Alan Meds vs Invyncible
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Alan Meds
Best for budget-conscious shoppersStarting at $99/mo
Invyncible
Best for Florida-region buyers seeking a corporate-parent-disclosed telehealth GLP-1 platform with a verifiable LegitScript seal and clear accountability address, who are willing to sign up to see specific pricing, drug forms, and pharmacy partner details.Side-by-Side Comparison
| Feature | Alan Meds | Invyncible |
|---|---|---|
| Overall Score | ✓7.7/10 | 5.8/10 |
| Starting Price | $99/mo | — |
| Editorial Rating | ✓3.9 ★ /5 | 2.9 ★ /5 |
| Features | 5 features | ✓7 features |
| States Available | ✓46 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Alan Meds
Pros
- ✓Aggressively low monthly pricing
- ✓Both semaglutide and tirzepatide available
- ✓Compounded GLP-1 access
- ✓Multiple administration formats
Cons
- ✗Limited public information on program details
Invyncible
Pros
- ✓Corporate parent EXPLICITLY disclosed (Nationwide Telemedicine, LLC) — better than the majority of DTC competitors that hide ownership behind trade names
- ✓Physical corporate address published (204 37th Ave N., #337 St. Petersburg, FL 33704) — accountability signal
- ✓LegitScript verification seal displayed — basic certification signal
- ✓No long-term commitment framing reduces sign-up friction
- ✓Both semaglutide and tirzepatide programs offered
Cons
- ✗Pricing tiers NOT disclosed on the public homepage — fully gated behind sign-up flow
- ✗Specific drug forms (compounded vs brand-name; injection vs oral) NOT disclosed on homepage
- ✗503A vs 503B compounding designation NOT specified
- ✗Pharmacy partner NOT named
- ✗LegitScript ID NUMBER not publicly visible (only the seal)
- ✗States-served list NOT disclosed publicly
- ✗Named medical director / clinical leadership NOT disclosed
- ✗FDA compounded-medication disclaimer NOT published on the homepage
- ✗Site is JavaScript-rendered SPA — subpaths /pricing, /semaglutide, /programs all return 404 via standard URL guessing; most content gated behind /get-started flow
- ✗Governing law / arbitration venue NOT disclosed publicly
- ✗Refund policy details NOT disclosed beyond 'no long-term commitment' framing
Our Verdict
Alan Meds edges out Invyncible with a higher overall score of 7.7/10 and is particularly strong for budget-conscious shoppers. Invyncible remains a solid alternative, especially if you're looking for Florida-region buyers seeking a corporate-parent-disclosed telehealth GLP-1 platform with a verifiable LegitScript seal and clear accountability address, who are willing to sign up to see specific pricing, drug forms, and pharmacy partner details..
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.